Cargando…
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
BACKGROUND: Tyrosine kinase inhibitor (TKI) treatment has significantly improved the prognosis of oncogenic-driven lung adenocarcinoma (LUAD). However, drug resistance limits the long-term benefits of patients. Therefore, there is a pressing need to explore the mechanism of TKI resistance and identi...
Autores principales: | Zhang, Chuanfen, Wang, Chunmei, Yang, Zhenyu, Bai, Yuquan, Shukuya, Takehito, Poh, Mau-Ern, Ekman, Simon, Li, Jian, Xu, Yuyang, Deng, Senyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186177/ https://www.ncbi.nlm.nih.gov/pubmed/35693278 http://dx.doi.org/10.21037/tlcr-22-318 |
Ejemplares similares
-
Erratum to identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
Publicado: (2022) -
A six-long noncoding RNA model predicts prognosis in lung adenocarcinoma
por: Bai, Yuquan, et al.
Publicado: (2020) -
Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer
por: Bai, Yuquan, et al.
Publicado: (2023) -
Identifies Immune Feature Genes for Prediction of Chemotherapy Benefit in Cancer
por: Bai, Yuquan, et al.
Publicado: (2022) -
The Significance of MMP-1 in EGFR-TKI–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
por: Saito, Ryoko, et al.
Publicado: (2018)